The Digital Pathology Market is poised to reach $1.86 billion by 2030, exhibiting a CAGR of 8.7% from 2024 to 2030. Digital pathology entails the interpretation and management of pathology information derived from digitized glass slides. It has become a mainstream choice for routine diagnostics and drug development. The adoption of digital pathology has surged owing to its diverse advantages, such as real-time sharing of video streams and digital images. Moreover, the integration of machine learning (ML) allows image assessments beyond traditional histopathology by connecting AI with clinical data.
Furthermore, the rising adoption of digital pathology has led to the emergence of virtual pathology, creating new opportunities for teleconsulting. Moreover, computer-aided diagnosis by digital images produces more precise and accurate results than a traditional microscope offering. The technology is gaining prominence due to growing requirements in anatomical pathology applications for quantitative image analysis. These emerging imaging tools enable pathologists to conduct more consistent and accurate diagnoses.
Increasing Adoption of Digital Pathology Solutions to Enhance Lab Efficiency
Digital pathology enables pathologists to collaborate and work remotely on cases by improving the accuracy of diagnostic techniques and allowing the sharing of digital images beyond geographical limitations. Before the outbreak of COVID-19, the adoption of digital pathology was extremely low due to stringent federal regulations of the U.S. FDA. The adoption increased due to the relaxation of FDA requirements for validating and approving digital pathology-related technology to meet the increased demand during the pandemic. Furthermore, the Centers for Medicare & Medicaid Services waived the Clinical Laboratory Improvement Amendments restrictions, allowing pathologists to use digital pathology platforms from their homes. Hence, the COVID-19 pandemic supported the adoption of digital pathology, allowing pathologists and physicians to deliver remote support & care to patients.
According to the data released by Pathcore Inc. (Canada) in January 2020, the number of pathologists in the U.S. is declining. Amid the decline in the number of pathologists and the rise in workloads, many pathologists are adopting digital pathology tools with AI in their clinical practice. AI allows pathologists to conduct preliminary assessments for high-risk and complex cases and manage the vast amount of data created for improving pathologic classification, diagnosis, and disease predictions.
Click here to: Get Free Sample Copy of this report
Rising Prevalence of Chronic Diseases
According to the Centers for Disease Control and Prevention, chronic diseases such as cancer, diabetes, and cardiovascular diseases are major causes of disability and death in the U.S. and account for USD 4.1 trillion of the nation’s annual healthcare costs. As of July 2022, six in ten adults have a chronic disease in the U.S. and four in ten suffer from two or more chronic diseases.
As per the data published by the WHO, it is expected that by 2030, 1 in six people globally will be more than 60 years old. By 2050, the global population aged 60 and above is likely to increase to nearly 2.1 billion. Additionally, the number of individuals aged 80 or older is expected to reach 426 million between 2020 and 2050. The prevalence of chronic diseases is higher among the elderly population. Thus, the rising aging population and the subsequent increase in cancer & other chronic diseases are expected to drive the demand for more precise and accurate diagnosis, driving the growth of the digital pathology market.
Key Findings in the Global Digital Pathology Market Study:
Based on offering, the hardware segment is expected to account for the largest share of the market in 2024
The large market share of this segment is attributed to the increasing number of laboratories, the rising number of patients requiring in vitro tests, and the growing need for timely and accurate disease treatment. The hardware segment is further subsegmented into tissue microarrays, scanners, and other hardware. The large market share of the hardware segment is attributed to the increased demand for scanners for R&D activities, the rising prevalence of chronic diseases, and the high adoption of digital pathology systems.
Based on application, the disease diagnosis segment is expected to account for the largest share of the market in 2024
The large market share of this segment is attributed to the high burden of chronic diseases, the high adoption of teleconsulting, and the rising awareness about the importance of early disease diagnosis is driving the demand for digital pathology solutions.
Based on end user, in 2024, the hospitals & clinics segment is expected to account for the largest share of the market
The large market share of this segment is attributed to the rising number of hospitals & clinics, the rise in the number of hospitalizations for the treatment of chronic diseases, and the increasing installation of digital pathology systems and tools in the healthcare sector in developed countries. Additionally, strategic collaborations among hospitals and key market players for launching advanced products are expected to drive the market’s growth. For instance, in May 2022, Sectra AB (Sweden) signed an agreement with UniHA, a cooperative of French public hospitals, for Spectra’s digital pathology. This agreement enabled the hospitals to purchase Sectra’s solution without undertaking a public tender process on preconditioned terms and conditions.
Asia-Pacific: Fastest-growing Regional Market
The growth of this regional market is attributed to the increasing geriatric population in countries such as China and India, the rising adoption of advanced healthcare solutions in developing countries, the rising disposable incomes among the population, and the rising awareness about the advantages of digital pathology.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players between 2020 and 2022. The key players profiled in the digital pathology market report are 3DHISTECH Ltd. (Hungary), Leica Microsystems (a subsidiary of Danaher Corporation) (Germany), Hamamatsu Photonics K.K. (Japan), Nikon Corporation (Japan), Visiopharm A/S (Denmark), Koninklijke Philips N.V.(Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Glencoe Software, Inc. (U.S.), XIFIN, Inc. (U.S.), and PerkinElmer Inc.(U.S.).
Scope of the Report:
Digital Pathology Market, by Offering
- Hardware
- Slide Scanners
- Bright Field
- Other Scanners
- Tissue Microarray
- Other Hardware
- Software
- Image Analysis Software
- Information Management System
- Other Software
- Services
(Note 1: Other Hardware includes Clinical Microscopes and Accessories.)
(Note 2: Other Software includes Digital Storage Systems, Tissue Microarray Software, and Telepathology Platforms.)
Digital Pathology Market, by Application
- Disease Diagnosis
- Drug Discovery & Development
- Education & Training
- Teleconsultation
Digital Pathology Market, by End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Diagnostic Laboratories
Digital Pathology Market, by Geography
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Key questions answered in the report:
